Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.607 USD -0.83% Market Closed
Market Cap: 138.1m USD
Have any thoughts about
Vaxart Inc?
Write Note

Operating Margin
Vaxart Inc

-427.8%
Current
-19 693%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-427.8%
=
Operating Profit
-71.7m
/
Revenue
16.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Vaxart Inc
NASDAQ:VXRT
138.1m USD
-428%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
314.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-22%
Country US
Market Cap 138.1m USD
Operating Margin
-428%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 314.7B USD
Operating Margin
28%
Country US
Market Cap 147.4B USD
Operating Margin
19%
Country US
Market Cap 119.4B USD
Operating Margin
40%
Country US
Market Cap 113.8B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.4B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.3B EUR
Operating Margin
-22%
No Stocks Found

Vaxart Inc
Glance View

Market Cap
138.1m USD
Industry
Biotechnology

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

VXRT Intrinsic Value
0.666 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-427.8%
=
Operating Profit
-71.7m
/
Revenue
16.8m
What is the Operating Margin of Vaxart Inc?

Based on Vaxart Inc's most recent financial statements, the company has Operating Margin of -427.8%.